


**Figure S2: Effect of allocation to simvastatin plus ezetimibe on all major vascular events in SHARP**



CI, confidence interval; CVD, cardiovascular disease; CKD, chronic kidney disease; LDL-C, LDL cholesterol.

<sup>†</sup>83% of participants in this category with chronic kidney disease (CKD) stage 3b (eGFR ≥30 to <45 ml/min/1.73m<sup>2</sup>)